Knowledge-Based Firm in Iran Begins Mass Production, Exporting
Hadi Hazrati, the director of quality control department of the knowledge-based firm, told local Iranian media that the company operates in two different fields of chemical drugs and biotechnology, adding, “The first biotechnology drug product of this company is Alteplas. The drug is a recombinant human tissue-type plasminogen activator that directly converts plasminogen to active plasmin and causes fibrin clot dissolution.”
Alteplase injection is used to dissolve blood clots that have formed in the blood vessels. It is used immediately after symptoms of a heart attack occur to improve patient survival. It is also used after symptoms of a stroke and to treat blood clots in the lungs (pulmonary embolism).
Hazrati said that their company makes Iran the second country to produce Alteplase after Germany.
“If this drug is injected in its right time, it can save the patient’s life. The best time to inject this drug is 60 minutes after the onset of heart attack or stroke symptoms,” Hazrati said.
“He described Alteplase as a drug with enzyme activity that converts plasminogen into plasmin upon entering the body. The role of plasmin in the body is to open and break down blood clots formed in blood vessels,” he added.
The director of quality control the company stated that this drug is produced in an injectable format, adding that the drug is in the form of a lyophilized powder that is dissolved in a solvent and based on the patient's weight, a special dose for that person is injected into the vein.
“Oman, Venezuela, Iraq and Bosnia and Herzegovina are our target markets for export. We hope to enter global markets by obtaining GMP standards,” he continued.
“By the end of this year, in addition to meeting the country's need for this drug, we are trying to export it. Currently, the annual production capacity of this company is 20,000 to 30,000 vials, and the country's need for this drug is 40,000 vials annually, and we will increase the production capacity of this drug by the end of the year, he further asserted.
According to him, these types of drugs are only available to emergency rooms.
4155/i
